A Phase 2 interventional study of Finerenone Oral Tablet and Placebo in Kidney Transplant; Complications, sponsored by University of North Carolina, Chapel Hill. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by University of North Carolina, Chapel Hill · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Albuminuria with a site in United States — 9 open to participants now, 11 under way, none of them phase 3. Albuminuria · United States.
Among the 50 studies in Albuminuria with a site in United States, this one is the 18th largest by planned enrollment of the 42 interventional ones that give a count, is the only one that started in 2024, is one of 15 in phase 2, and was the 43rd registered.
144 studies on the registry are indexed under Albuminuria; 25 are open to participants now.
Browse Albuminuria studies →9 of the 50 studies in Albuminuria with a site in United States are open now. Recruiting first, the newest first:
Geisinger Clinic · Sites in United States
Ages 18+
University of Illinois at Chicago · Sites in United States
Ages 18–60
University of Colorado, Denver · Sites in United States
Ages 18–80
University of Tennessee · Sites in United States
Ages 18–65
Wake Forest University Health Sciences · Sites in United States
Ages 7–18 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Albuminuria studies recruiting now, 4 (31%) set no upper age limit and 5 (38%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 17 · Phase 3 4 · Phase 4 6
First in 2001; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 69 across 117 interventional studies indexed under Albuminuria.
Median enrollment 60 across the 42 interventional studies, 403 across the 8 observational. Of the 38 that completed or were terminated, 20 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 50 have an industry lead sponsor. The 10 most frequent:
University of North Carolina, Chapel Hill is the lead sponsor of 1,373 studies on the registry; 134 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 140 (86%) have results posted.
University of North Carolina, Chapel Hill has 2 studies filed under Albuminuria — fewer than ten, so there is no comparison to draw.
3 of the studies in Albuminuria with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04752293Wake Forest University Health SciencesPediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE) | 2026-12 |
| NCT05498116University of Colorado, DenverEffect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes | 2027-02 |
| NCT06059664University of North Carolina, Chapel HillThe EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 50 studies in Albuminuria with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
EFFEKTOR is a vanguard, multicenter, phase 2 randomized, double blinded, placebo controlled clinical trial to determine the feasibility, tolerability, safety, and efficacy of finerenone in kidney transplant recipients (KTRs). One hundred fifty (150) KTRs will be randomized in a 2:1 ratio of finerenone to placebo, with two embedded substudies: (i) a kidney biopsy substudy in 50 participants who undergo a research kidney biopsy prior to randomization and at the end of active treatment; and (ii) a functional MRI (fMRI) substudy in 50 participants who undergo fMRI prior to randomization and at the end of active treatment.
Kidney transplantation yields significant improvements in morbidity, mortality, and quality of life for patients with end-stage kidney disease (ESKD), however, the burden from progressive chronic kidney disease (CKD), cardiovascular (CV) events and death remain high. CKD is the result of several pathologic processes, including diabetic and hypertensive sclerosis, calcineurin inhibitor toxicity (CNIT), chronic inflammation and fibrosis that ensues post-acute rejection episodes and other nonspecific insults that can result in CKD mediators. Currently, mean allograft survival is currently 8 years and 12 years for deceased and living donor kidney transplants, respectively. More than 80% of KTRs are under 65 years and 60% under age 55 years, indicating most KTRs will either require a second transplant or eventually transition to maintenance dialysis which portends a poor prognosis and decreased quality of life. CV disease is also highly prevalent, with KTRs having 50 times the annual rate of fatal or nonfatal cardiovascular events and up to 10 times the rate of cardiac death as the general population. Specifically, heart failure is common, with 19% of KTRs sustaining a new diagnosis of heart failure just 3 years post-transplant, and a mean 5.7-7.1 Congestive heart failure (CHF) acute care utilization episodes per 100 person-years. Moreover, kidney and cardiovascular health are tightly intertwined, with kidney disease inciting and exacerbating cardiovascular pathology and vice versa. Thus, there is a critical need for improvements in post kidney transplantation cardiovascular morbidity, mortality, and allograft survival.
Finerenone, a potent, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA), has been shown to significantly reduce the risk of incident worsening CKD and ESKD, as well as preventing major adverse CV events and death in persons with diabetes and native CKD. The pathogenetic mechanisms through which finerenone acts are incompletely understood, but involve reduction of inflammation and fibrosis, key factors in the pathogenesis of CKD and CV disease in KTRs. Moreover, there are preliminary data to suggest that any renin-angiotensin aldosterone system (RAAS blockade), but particularly MRAs and finerenone, could be important to mitigating the effects of CNIT, a significant contributor to graft loss. While current, published clinical trials have been in people with type 2 diabetes and CKD, there is compelling evidence to suggest that these benefits will extend to people with CKD in the absence of diabetes.
Given the high cardiovascular and kidney disease burden in KTRs, and compelling evidence for finerenone in kidney and cardiac protection in patients with native CKD, a vanguard clinical trial of finerenone in 150 KTRs will be undertaken using a randomized, double blind, placebo-controlled study design over the course of 13 months.
Objective 1: To determine the feasibility of recruitment of KTRs to a clinical trial of finerenone with embedded kidney biopsy study. Finerenone is postulated to decrease the risk of kidney and cardiovascular events in KTRs, unrelated to the immunologic inciting factors or mediators of acute rejection episodes. In essence, it is hypothesized that the mechanisms by which finerenone decreases kidney and cardiovascular endpoints in people with type 2 diabetes (T2D) and native CKD, will be similarly effective in patients (regardless of diabetes status) living with a kidney transplant. It is unknown to what extent KTRs and their treating transplant physicians would be willing to participate in a clinical trial of a drug that is targeted at 'general' reduction of CKD and cardiovascular outcomes. In particular, this trial could help provide strategies for successful recruitment of KTRs into such trials.
Kidney tissue is a particularly valuable tool for identifying mechanisms through which finerenone may decrease progression of interstitial fibrosis and CNIT in KTRs. Such information is deemed critical in helping to determine whether future, larger trials of KTRs are indicated, and whether kidney biopsy could be useful for stratifying participants (eg. based on the presence or degree of interstitial fibrosis). Kidney biopsy also yields valuable information helpful to clinical decisions in caring for KTRs but does come with some risks. Thus, the feasibility of enrolling KTRs to a 'not for cause' kidney biopsies in the context of a clinical trial targeting CKD and Cardiovascular Disease (CVD) is unknown.
Objective 2: To measure the tolerability and safety of finerenone in KTRs. Finerenone has not been administered in KTRs and it is unclear whether tolerability will be similar to that of people with diabetes (and perhaps those without) and CKD. The primary concerns include risks for hyperkalemia and creatinine fluctuations which may necessitate temporary or permanent withdrawal of finerenone and also result in downstream interventions specific to kidney transplantation. Immunosuppression for KTRs most often includes a calcineurin inhibitor (CNI) which increases the risk for hyperkalemia, as does finerenone. Moreover, many KTRs are also treated with renin angiotensin system (RAS) blockers, which only further increases this risk. This study will help determine the magnitude of this risk, optimal approaches to managing hyperkalemia specifically in KTRs, and which subpopulations are less likely to tolerate finerenone (eg. those on CNI and RAS blockers), in order to inform potential future clinical trials. The other concern for tolerability of finerenone in KTRs, is the tendency in clinical practice to discontinue medications with the potential to reduce eGFR in KTRs when creatinine levels rise, in order to assess whether rejection is in progress. Ultimately, if KTRs are not able to be maintained on finerenone for a reasonable period, it is unlikely that they would experience potential benefits either. Tolerability will be measured by the relative time on study drug in the two comparator groups.
Safety analyses will build further upon the outcomes of tolerability and will include: hyperkalemia (>5.5m Eq/L), other hyperkalemia-associated events designated by the investigator as requiring holding/discontinuing study drug or RAS blocker, and acute kidney injury episodes defined by Kidney Disease Improving Global Outcomes (KDIGO) criteria, infections requiring acute care (emergency room visits or hospitalization).
Objective 3: To determine the effect of finerenone on clinical, radiologic and pathologic kidney markers in KTRs. Finerenone decreases the risk for progression of CKD and CV events in people with T2D and CKD. It is likely that the effect is similar, regardless of diabetes status, and trials are underway to determine this. KTRs have several potential confounding factors relating to the pathogenesis of worsening kidney disease, namely use of CNIs, donor derived disease, BK virus associated nephropathy and other urinary tract infections, and both acute and chronic T cell or antibody mediated rejection, which may override any potential benefit from finerenone. Alternatively, the anti-inflammatory and antifibrotic effects of finerenone may be particularly beneficial in KTRs with chronic kidney dysfunction secondary to any of the above processes as the final common pathway that results in allograft dysfunction and failure in all of the above is inflammation and fibrosis.
CV disease is a major burden in KTRs, with event rates higher than in the general population, which may partly be related to the fact that most KTRs spend several years on dialysis prior to transplantation. KTRs are at also at high risk of other complicating/competing factors linked to CV events, including the vascular impact of immunosuppressive agents, infection and malignancy. It is unknown whether the complex health status and treatments of KTRs will alter the potential benefit of finerenone on CV events and death.
This relatively short-term trial will include multiple exploratory clinical, radiologic and pathologic endpoints. Exploratory clinical kidney and CV endpoints will focus on relative changes in albuminuria, eGFR slope and the relative difference in the need for acute care for congestive heart failure. Exploratory radiologic endpoints include kidney cortical perfusion, oxygenation and fibrosis as measured by fMRI, and pathologic parameters are to include changes in Banff classification, percent change in interstitial fibrosis using sirius red staining. Blood, urine and kidney specific cytokines and fibrotic markers will also be measured at baseline and at the end of active treatment.
Clinical Trial Inclusion Criteria:
Additional Inclusion Criteria for Kidney Sub-study:
Medical Condition Exclusion Criteria:
Concomitant Therapies Exclusion Criteria:
Other Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this study arm will receive the study drug Finerenone. Initial Dosing: Dosing regimen of 10 mg or 20 mg once daily (QD), based upon screening eGFR. For eGFR \< 60 mL/min/1.73m\^2, participants will start at 10 mg QD. For eGFR ≥ 60 mL/min/1.73m\^2, participants will start at 20 mg QD. Dose Titration: Dose will be titrated according to potassium levels. For participants initiated at 10mg, the dose will be up titrated to 20 mg if the potassium level measured after 2 weeks is ≤4.8 meq/L and eGFR has not decreased by \>30 percent of the screening visit value. Study drug dosing may be titrated up or down per the below. Potassium level: ≤ 4.8 * If on lower dose, up-titrate to higher dose * If on higher dose, continue on the same dose Potassium level: 4.9-5.5 = continue same dose Potassium level: \>5.5 = withhold study drug and recheck potassium within 3 days. Re-initiate study drug at the 10 mg dose once potassium is ≤4.8 meq/L.
Drug: Finerenone Oral Tablet
Participants in this study arm will receive the placebo comparator. Initial Dosing: Dosing regimen of 10 mg or 20 mg once daily (QD), based upon screening eGFR. For eGFR \< 60 ml/min/1.73m\^2, participants will start at 10mg QD. For eGFR ≥ 60ml/min/1.73m\^2, participants will start at 20 mg QD. Dose Titration: Dose will be titrated according to potassium levels. For participants initiated at 10 mg, the dose will be up titrated to 20 mg if the potassium level measured after 2 weeks is ≤4.8 meq/L and eGFR has not decreased by \>30 percent of the screening visit value. Study drug dosing may be titrated up or down per the table below. Potassium level: ≤ 4.8 * If on lower dose, up-titrate to higher dose * If on higher dose, continue on the same dose Potassium level: 4.9-5.5 = continue same dose Potassium level: \>5.5 = withhold study drug and recheck potassium within 3 days. Re-initiate study drug at the 10 mg dose once potassium is ≤4.8 meq/L.
Drug: Placebo
Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.
Also known as: Kerendia
Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.
Also known as: Sugar pill
Feasibility of recruitment to the main clinical trial: Total number of participants who were eligible and enrolled in the main clinical trial
Signed consent by 30 participants for the main clinical trial within 3 months of launching the full study protocol (date of first person randomized).
Time frame: Up to 3 months after launching the full study protocol
Feasibility of recruitment to the kidney biopsy substudy: Total number of participants who were eligible and enrolled in the kidney biopsy substudy
Signed consent by 10 participants for the biopsy substudy within 3 months of launching the full study protocol (date of first person randomized).
Time frame: Up to 3 months after launching the full study protocol
Relative tolerability of finerenone
Relative tolerability is defined as the percent time spent on the investigational product.
Time frame: From randomization to last on study drug visit, approximately 12 months
Risk for discontinuation of finerenone
The number of the participants who permanently discontinue the investigational product prior to the last on study drug visit, divided by the total number of study participants in the same treatment group.
Time frame: From randomization to last on study drug visit, approximately 12 months
Overall safety of finerenone
The percentage of participants suffering a serious adverse event or adverse event of interest (hyperkalemia, acute kidney injuries) while on study drug.
Time frame: From randomization to last on study drug visit, approximately 12 months
Adverse Event (AE) related to hyperkalemia
The percentage of participants requiring acute care (hospitalization or ER visit) for hyperkalemia, while on study drug.
Time frame: From randomization to last on study drug visit, approximately 12 months
Adverse Event (AE) related to acute kidney injury
The percentage of participants requiring acute care (hospitalization or ER visit) for acute kidney injury while on study drug.
Time frame: From randomization to last on study drug visit, approximately 12 months
Efficacy for albuminuria reduction
The relative Urine Albumin Creatinine Ratio (UACR) reduction between groups, with comparison testing using Kruskal Wallis test. The relative reduction in log transformed mean UACR = 1- logUACR(Last on-drug) / logUACR(Screen).
Time frame: From randomization to last on study drug visit, approximately 12 months
Efficacy for prevention of congestive heart failure (CHF)
Relative risk of CHF requiring acute care = \[total number of persons with an event in finerenone group/total number of participants in finerenone group\] divided by the \[total number of persons with an event in finerenone group/total number of participants in finerenone group\]
Time frame: From randomization to last on study drug visit, approximately 12 months
Efficacy for functional Magnetic Resonance Imaging (fMRI) kidney oxygenation
Difference between active versus placebo groups with respect to absolute change in fMRI measures of cortical oxygen availability, estimated by R2\* (s-1) using blood oxygenation level dependent (BOLD) MRI
Time frame: From within 2 weeks before randomization, within 2 weeks before last on study drug visit, up to 12.5 months
Efficacy for functional Magnetic Resonance Imaging (fMRI) kidney perfusion
Difference between active versus placebo groups with respect to absolute change in fMRI measures of cortical perfusion (ml/min/100g), estimated using arterial spin labeling (ASL) MRI
Time frame: From within 2 weeks before randomization, within 2 weeks before last on study drug visit, up to 12.5 months
Efficacy for functional Magnetic Resonance Imaging (fMRI) kidney fibrosis
Difference between active versus placebo groups with respect to absolute change in fMRI cortical fibrosis, estimated by apparent diffusion coefficient (ADC), (x10-3/s) using diffusion-weighted MRI.
Time frame: From within 2 weeks before randomization, within 2 weeks before last on study drug visit, up to 12.5 months
Efficacy for interstitial fibrosis and tubular atrophy (IFTA)
Difference between active versus placebo groups with respect to absolute change in percent of cortex with IFTA
Time frame: From within 2 weeks before randomization, within 2 weeks before last on study drug visit, up to 12.5 months
Plan to share: Yes — De-identified individual data that supports the results will be shared from 9 through 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: From 9 months through 36 months after publication
Access criteria: The investigator has approved IRB, IEC, or REB and an executed data use/sharing agreement with University of North Carolina (UNC).
Started Apr 2024 (actual). Primary completion is estimated for Mar 2027, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Finerenone
University of North Carolina, Chapel Hill →